PD-1/L1
GSK’s Jemperli Shows Promise in Endometrial Cancer Trial – FDA Label Expansion on the Horizon
GSK has achieved a significant milestone with its PD-1 inhibitor, Jemperli, in the treatment of endometrial cancer, potentially opening the ...
Imfinzi and Lynparza Combo Improves Survival in Endometrial Cancer Trial (ESMO 2023)
ESMO 2023: LBA41 AstraZeneca is exploring a potentially powerful approach in the fight against endometrial cancer, suggesting that combining their ...
ESMO 2023: GSKās Jemperli beats Merckās Keytruda in lung cancer survival trial
In a groundbreaking clinical trial, GSK has achieved remarkable patient survival results with its PD-1 inhibitor, Jemperli, when compared to ...
Keytruda approved by FDA for early-stage lung cancer surgery, with a twist
In a groundbreaking development, the FDA has granted approval for Merck’s Keytruda to be employed in a continuous immunotherapy regimen ...
Merckās Keytruda extends survival of early lung cancer patients in trial, awaits FDA approval
Merck & Co.’s Keytruda has achieved a groundbreaking milestone in the treatment landscape for early-stage non-small cell lung cancer (NSCLC), ...
Keytruda shows promise in bladder cancer trial, Merck says
Merck’s immunotherapy drug, Keytruda, continues to demonstrate success in the field of bladder cancer. After securing FDA approvals for use ...
Opdivo plus chemo reduces recurrence risk in early-stage lung cancer surgery
In the arena of perioperative treatment for early-stage non-small cell lung cancer (NSCLC) involving PD-1/L1 inhibitors, the competition among key ...
